New cancer cachexia treatment boosts weight gain and patient …
WEB23 hours ago · New cancer cachexia treatment boosts weight gain and patient activity. A nationwide clinical trial shows positive results for cancer patients with this common wasting syndrome. Researchers ...
New Cancer Cachexia Treatment Boosts Weight Gain and Patient …
WEB1 day ago · New Cancer Cachexia Treatment Boosts Weight Gain and Patient Activity. Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and muscle wasting. The results of …
Drug breakthrough provides new hope for cancer patients with cachexia
WEB1 day ago · Drug breakthrough provides new hope for cancer patients with cachexia. Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see ...
New therapy shows promise in improving appetite, quality of life …
WEB5 days ago · New clinical trial results published in The New England Journal of Medicine suggest a promising new therapy could help patients with cachexia, a condition that causes weight, muscle, and fat loss, as well as weakness in people with cancer.
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab …
WEBSep 14, 2024 · NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15. Cachexia is a common, life-threatening wasting condition that can ...
ESMO 2024: Positive Phase II results for Pfizer’s ponsegromab in …
WEB4 days ago · The Phase II study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15, said US pharma giant Pfizer.
Pfizer's cancer cachexia drug shows positive midstage trial results
WEBSep 14, 2024 · The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for cancer cachexia.
Pfizer Presents Positive Data from Phase 2 Study of ... - Nasdaq
WEB6 days ago · Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia Published Sep 14, 2024 8:45am EDT
Ponsegromab for the Treatment of Cancer Cachexia | NEJM
WEB6 days ago · In a small, open-label, phase 1b study involving patients with cancer cachexia, ponsegromab, a humanized monoclonal antibody inhibiting GDF-15, was associated with improved weight, appetite, and...
Molecular basis for muscle loss that causes cachexia - Nature
WEBMay 10, 2023 · Cachexia-related muscle loss, or atrophy, is characterized by excessive protein degradation and a reduction in protein synthesis. A combination of dietary and exercise regimes is thought to ...
Skip to content